| Annual · values | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | -1.89 M USD | -3.92 M USD | -2.85 M USD | -2.24 M USD |
| Depreciation & Amortization | 1.15 M USD | 1.12 M USD | 1.12 M USD | 1.11 M USD |
| Stock-Based Compensation | 13000 USD | 19000 USD | — | — |
| Capital Expenditures | — | — | — | — |
| Cash Flow from Investing | 3000 USD | 2000 USD | -15000 USD | -349000 USD |
| Cash Flow from Financing | -109000 USD | 5.92 M USD | 2.87 M USD | 2.55 M USD |
| Dividends Paid | — | — | — | — |
| Stock Buybacks | — | — | — | — |
| Free Cash Flow | — | — | — | — |
Impact Biomedical Inc. is a pioneering company within the biotechnology sector, focused on developing innovative solutions that address key challenges in health and wellness. The primary function of Impact Biomedical Inc. is to research and create cutting-edge biotechnologies that have the potential to significantly impact pharmaceuticals, cosmetics, and other health-related industries. Notable features of the company include its strong emphasis on developing anti-pathogenic compounds, next-generation health supplements, and immunotherapy treatments. Impact Biomedical collaborates with research institutions and global partners to leverage scientific advancements and bring novel products to the market. As a player in the biotech market, Impact Biomedical Inc. plays a crucial role in advancing medical science and providing tools that combat health threats, contributing to the overall development and enhancement of public health solutions. Its innovations are particularly significant as they promise improvements in treatment efficacy and accessibility, thereby influencing various sectors aligned with health and disease prevention.